Health
Ascletis Enters the Obesity Drug Space with Announcement of Two Ongoing U.S. Phase I Clinical Trials Utilizing Its Small Molecule GLP-1R Agonist ASC30 for Both Once-Monthly Subcutaneous Injection and Once-Daily Oral Tablet for the Treatment of Obesity
- ASC30 is the first and only small molecule GLP-1 receptor (GLP-1R) agonist that can be dosed once-monthly subcutaneously and once-daily orally to treat obesity - ASC30 is two- to threefold more potent, in vitro, than orforglipron and stimulated significantly greater insulin secretion when comp...
2024-09-17 18:25
2156
Subgroup Analysis from Pivotal WU-KONG1B Study Exhibits Robust Efficacy of Sunvozertinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations Across Different Baseline Characteristics
Results of subgroup analysis from the pivotal WU-KONG1B study in relapsed or refractory NSCLC with EGFR exon20ins presented at ESMO 2024 * Sunvozertinib demonstrated promising anti-tumor efficacy, regardless of EGFR exon20ins region classification, race, region, baseline brain metastasis, prio...
2024-09-17 15:47
1857
Gates Foundation Report Calls for Targeted Global Health Spending to Save Millions of Children from Malnutrition and Disease
New modeling shows 40 million more children will suffer from hunger's worst effects by 2050 due to climate change, but immediate action could instead boost health, spur economic growth SEATTLE, Sept. 17, 2024 /PRNewswire/ -- In its eighth annual Goalkeepers report released today, the Bill & Meli...
2024-09-17 12:01
1785
WestGene Biopharma Presents Groundbreaking mRNA Vaccine Data at ESMO 2024
BARCELONA, Spain, Sept. 16, 2024 /PRNewswire/ -- WestGene Biopharma, a leading innovator in mRNA therapeutics, presented the latest clinical data for its EBV-positive tumour mRNA vaccine, WGc-043, during a mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024. ...
2024-09-17 00:01
1318
TraceLink Co-Founder and SVP of Supply Network Products Lucy Deus Named Recipient of 2024 Women in Supply Chain Award
Deus was recognized in the Trailblazers category, which honors female leaders who continue to pave the way for future women in logistics BOSTON, Sept. 16, 2024 /PRNewswire/ -- TraceLink, the only no-code platform for intelligent orchestration of end-to-end supply chains, proudly announces thatLu...
2024-09-16 23:34
1573
Sirtex Medical Announces Certification of SIR-Spheres® Y-90 Resin Microspheres According to Medical Device Regulation (EU) 2017/745 and European Launch of the Innovative SIROS™ Delivery System
Sirtex brings an innovative liver cancer treatment delivery system to Europe, enhancing options for physicians and their patients. WOBURN, Mass., Sept. 16, 2024 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional treatment solutions, today announced that it has re...
2024-09-16 21:00
1537
Argon Medical Launches CLEANER Vac™ Thrombectomy System to Remove Blood Clot in the Peripheral Venous Vasculature
PLANO, Texas, Sept. 16, 2024 /PRNewswire/ -- Argon Medical Devices, a leading provider of medical device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology procedures, announced the launch of the CLEANER Vac™ Thrombectomy System for the removal of bl...
2024-09-16 20:47
1472
Concord Medical Announces Obtaining Large Medical Equipment Procurement License for Its Proton Therapy Equipment
BEIJING, Sept. 16, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that Guangzhou Concord Cancer Center ("Guangzhou H...
2024-09-16 20:00
1978
Vazyme Leads Life Science Innovation, Boosting Research Breakthroughs in mIDH1 Cancer Treatment
NANJING, China, Sept. 16, 2024 /PRNewswire/ -- Vazyme (688105.SH), a leading life science technology company, significantly contributed to groundbreaking research published in Science Magazine through its innovative products. The study, which focuses on how mutant IDH1 inhibition activates tumor ...
2024-09-16 19:00
1790
Antennova Releases Latest Data of CD73 Inhibitor ATN-037, including a DCR of 89.5%, in a Mini Oral at ESMO Congress 2024
* In patients with non-small cell lung cancer (NSCLC) or melanoma who had acquired resistance to checkpoint inhibitors (CPIs), ATN-037 in combination with KEYTRUDA®(pembrolizumab) demonstrated an overall response rate (ORR) of 21.1% and a disease control rate (DCR) of 89.5%. * Data from the...
2024-09-16 18:00
2040
Akeso's Ivonescimab plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety at ESMO 2024
HONG KONG, Sept. 16, 2024 /PRNewswire/ -- At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK) published the phase 2 results from its ivonescimab in combination with chemotherapy as a first-line (1L) treatment for triple-negative breast cancer (TNBC). The prelimina...
2024-09-16 15:35
4463
Alphamab Oncology Presented the Latest Clinical Data from Two Studies on Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024
SUZHOU, China, Sept. 16, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from two studies on anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 were presented at the 2024 European Society for Medical Oncology Congress (ESMO Congress 202...
2024-09-16 13:03
1957
"Transfersome Gel" a New Solution for Hypertrophic Scars Chula Pharmacy's Latest Innovation
BANGKOK, Sept. 16, 2024 /PRNewswire/ -- Lecturers at the Faculty of
Pharmaceutical Sciences,Chulalongkorn University
2024-09-16 10:00
1857
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
SHENZHEN, China, Sept. 15, 2024 /PRNewswire/ -- ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer (NMIBC). The results were published through post...
2024-09-15 17:53
3132
Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024
Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated HONG KONG, Sept. 15, 2024 /PRNewswire/ -- At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso released the Phase 2 clinical results of its internally developed PD-1/VEGF bispecific antibody, ivonescimab, with or...
2024-09-15 15:10
2939
Dialogue with CGT Leaders! You Are Invited to Join the "2024 GenScript Biotech Global Forum•London" to Discuss the Future Together
PISCATAWAY, N.J., Sept. 14, 2024 /PRNewswire/ -- The year 2024 marks a milestone year for continuous advancements in Cell and Gene Therapy (CGT). The global launch of Amtagvi, a Tumor-Infiltrating Lymphocyte (TIL) therapy, has ushered in a new era for solid tumor treatment using cell therapy. PM3...
2024-09-15 06:53
1951
Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration
NANJING, China, Sept. 14, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation by the U...
2024-09-14 19:43
3493
Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)
* In Phase Ia clinical study, GZR4 demonstrated favorable safety and tolerability profiles in healthy subjects, maintaining a stable glucose-lowering effect for up to one week with a single administration. * In Phase Ib clinical study, patients with Type 2 diabetes mellitus (T2DM) receiving s...
2024-09-14 19:00
4010
Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Sept. 14, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immuno...
2024-09-14 16:06
3565
NiceTop™️ Unveils New Hair Growth Supplement Amid Product Line Expansion
PLEASANTON, Calif., Sept. 13, 2024 /PRNewswire/ -- NiceTop™️, a U.S.-based anti-aging research team, has launched a new hair growth supplement, marking its latest foray into the personal care and nutrition market. The NiceTop™️ brand team, founded in 2012, announced the release of NiceTop™️ Hair...
2024-09-14 12:21
1265
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5214
